• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

趋化因子 CXCL12 和 CX3CL1 及其受体在人神经鞘瘤中的表达。

Expression of the chemokines CXCL12 and CX3CL1 and their receptors in human nerve sheath tumors.

机构信息

Department of Anatomy, University of Kiel, Kiel, Germany.

出版信息

Histol Histopathol. 2013 Oct;28(10):1337-49. doi: 10.14670/HH-28.1337. Epub 2013 May 6.

DOI:10.14670/HH-28.1337
PMID:23645563
Abstract

Peripheral nerve sheath tumors are in most cases slowly growing neoplasms that can be adequately cured by surgical resection. However, facing the risk of a neurosurgical intervention and the trend of multiple relapses of nerve sheath tumors the development of additional therapy strategies seems to be favourable, and therefore substantiated knowledge of molecular and cellular mechanisms in nerve sheath tumors should be achieved. Here, we firstly describe the expression of the chemokines CXCL12 (SDF-1) and CX3CL1 (fractalkine) and their respective receptors CXCR4, CXCR7 and CX3CR1 in different entities of human nerve sheath tumors and normal control tissues. Both ligands and their receptors are expressed in high to moderate levels on mRNA and protein level in benign and malignant nerve sheath tumors. While CXCL12 was mainly found in schwannoma cells (S100⁺) in situ, its receptor CXCR4 is also partly found on CD11b-positive macrophages / microglia and its alternative receptor CXCR7 is also expressed by endothelial cells and macrophages. CX3CL1 is expressed by parts of the schwannoma and endothelial cells, whereas its receptor CX3CR1 is expressed by nearly all tumor cells and macrophages, but not by endothelial cells. Taken together, we could show the presence of CXCL12 and CX3CL1 and their respective receptors in benign and malignant human nerve sheath tumors. Further investigations may show their functional role in health and disease.

摘要

周围神经鞘瘤在大多数情况下是生长缓慢的肿瘤,可以通过手术切除充分治愈。然而,面对神经外科干预的风险和神经鞘瘤多次复发的趋势,开发额外的治疗策略似乎是有利的,因此应该获得神经鞘瘤中分子和细胞机制的充分知识。在这里,我们首先描述了趋化因子 CXCL12(SDF-1)和 CX3CL1( fractalkine)及其各自的受体 CXCR4、CXCR7 和 CX3CR1 在不同人类神经鞘瘤实体和正常对照组织中的表达。在良性和恶性神经鞘瘤中,配体及其受体在 mRNA 和蛋白水平上均以高到中度水平表达。虽然 CXCL12 主要存在于神经鞘瘤细胞(S100⁺)原位,但它的受体 CXCR4 也部分存在于 CD11b 阳性巨噬细胞/小胶质细胞上,其替代受体 CXCR7 也由内皮细胞和巨噬细胞表达。CX3CL1 由部分神经鞘瘤和内皮细胞表达,而其受体 CX3CR1 则由几乎所有肿瘤细胞和巨噬细胞表达,但不表达于内皮细胞。综上所述,我们可以证明 CXCL12 和 CX3CL1 及其各自的受体存在于良性和恶性人类神经鞘瘤中。进一步的研究可能会显示它们在健康和疾病中的功能作用。

相似文献

1
Expression of the chemokines CXCL12 and CX3CL1 and their receptors in human nerve sheath tumors.趋化因子 CXCL12 和 CX3CL1 及其受体在人神经鞘瘤中的表达。
Histol Histopathol. 2013 Oct;28(10):1337-49. doi: 10.14670/HH-28.1337. Epub 2013 May 6.
2
The transmembrane chemokines CXCL16 and CX3CL1 and their receptors are expressed in human meningiomas.跨膜趋化因子 CXCL16 和 CX3CL1 及其受体在人脑膜瘤中表达。
Oncol Rep. 2013 Feb;29(2):563-70. doi: 10.3892/or.2012.2164. Epub 2012 Dec 3.
3
Expression and Cellular Localization of CXCR4 and CXCL12 in Human Carotid Atherosclerotic Plaques.CXCR4 和 CXCL12 在人颈动脉粥样硬化斑块中的表达及细胞定位。
Thromb Haemost. 2018 Jan;118(1):195-206. doi: 10.1160/TH17-04-0271. Epub 2018 Jan 5.
4
Profiling of Cxcl12 receptors, Cxcr4 and Cxcr7 in murine testis development and a spermatogenic depletion model indicates a role for Cxcr7 in controlling Cxcl12 activity.对小鼠睾丸发育和生精细胞耗竭模型中Cxcl12受体Cxcr4和Cxcr7的分析表明,Cxcr7在控制Cxcl12活性中发挥作用。
PLoS One. 2014 Dec 2;9(12):e112598. doi: 10.1371/journal.pone.0112598. eCollection 2014.
5
Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.CXCL12/CXCR4/CXCR7 轴在膀胱癌发病机制中的生物学/病理学功能。
Int J Clin Oncol. 2017 Dec;22(6):991-1000. doi: 10.1007/s10147-017-1187-x. Epub 2017 Oct 11.
6
Expression of chemokines and chemokine receptors in brain tumor tissue derived cells.趋化因子及趋化因子受体在脑肿瘤组织衍生细胞中的表达
Asian Pac J Cancer Prev. 2014;15(17):7201-5. doi: 10.7314/apjcp.2014.15.17.7201.
7
Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.炎症性CXCL12 - CXCR4/CXCR7轴介导G蛋白信号通路,影响鼻咽癌细胞的侵袭和迁移。
Tumour Biol. 2016 Jun;37(6):8169-79. doi: 10.1007/s13277-015-4686-2. Epub 2015 Dec 29.
8
Differential effects of CXCR4-CXCL12- and CXCR7-CXCL12-mediated immune reactions on murine P0106-125 -induced experimental autoimmune neuritis.CXCR4-CXCL12和CXCR7-CXCL12介导的免疫反应对小鼠P0106-125诱导的实验性自身免疫性神经炎的不同影响。
Neuropathol Appl Neurobiol. 2013 Dec;39(7):772-87. doi: 10.1111/nan.12039.
9
The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.趋化因子受体CXCR4/CXCR7及其主要异二聚体配体CXCL12和CXCL12/高迁移率族蛋白盒1在胰腺癌生长和发展中的作用:探索进展
Pancreas. 2015 May;44(4):528-34. doi: 10.1097/MPA.0000000000000298.
10
The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors.C-X-C基序趋化因子受体4在散发性恶性外周神经鞘瘤患者中的预后价值
Chin J Cancer. 2017 Oct 11;36(1):80. doi: 10.1186/s40880-017-0246-z.

引用本文的文献

1
Microglia-derived CXCL2 induced neuronal ferroptosis via CXCR2/Jun axis in sepsis-associated encephalopathy.小胶质细胞衍生的CXCL2通过CXCR2/Jun轴在脓毒症相关性脑病中诱导神经元铁死亡。
Front Immunol. 2025 Mar 6;15:1512300. doi: 10.3389/fimmu.2024.1512300. eCollection 2024.
2
Biomarkers in Vestibular Schwannoma-Associated Hearing Loss.前庭神经鞘瘤相关性听力损失中的生物标志物
Front Neurol. 2019 Sep 18;10:978. doi: 10.3389/fneur.2019.00978. eCollection 2019.
3
CXCR4: A new player in vestibular schwannoma pathogenesis.CXCR4:前庭神经鞘瘤发病机制中的新角色。
Oncotarget. 2018 Jan 10;9(11):9940-9950. doi: 10.18632/oncotarget.24119. eCollection 2018 Feb 9.
4
Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1.与Twist-1相比,Akirin-2的下调能更有效地提高人胶质母细胞瘤的化疗敏感性。
Oncotarget. 2015 Aug 28;6(25):21029-45. doi: 10.18632/oncotarget.3763.